Prostate-specific antigen in acute hepatitis and hepatocellular carcinoma

Prostate

Volumn 41, Issue 4, 1999, Pages 258-262

  Malavaud, Bernard ^a   Miédougé, Marcel ^b   Payen, Jean Louis ^a   Izopet, Jacques ^a   Rischmann, Pascal ^a   Pascal, Jean Pierre ^a   Sarramon, Jean Pierre ^a   Serre, Guy ^b  

^a CHU PURPAN   (France)

^b UNIVERSITÉ PAUL SABATIER   (France)

Author keywords

Acute hepatitis; Hepatocellular carcinoma; Prostate specific antigen

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA FETOPROTEIN; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; PROSTATE SPECIFIC ANTIGEN; PROTHROMBIN;

ACUTE HEPATITIS; ADOLESCENT; ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CYTOLYSIS; DIAGNOSTIC VALUE; DISEASE MARKER; FEMALE; HUMAN; IMMUNOASSAY; LIVER; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTHROMBIN TIME; RELIABILITY; SCHOOL CHILD;

EID: 2442743843     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0045(19991201)41:4<258::AID-PROS6>3.0.CO;2-1     Document Type: Article

References (37)

1. Wang WC, Valenzuela LA, Murphy GP, Chu TM. Purification of a human prostate-specific antigen. Invest Urol 1979;17:159-163.
2. Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 1987;317:909-916.
3. Oesterling JE. Prostate-specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol 1991;145:907-923.
4. Malavaud B, Salama G, Miédougé M, Vincent C, Rischmann P, Sarramon JP, Serre G. Influence of digital rectal massage on urinary prostate-specific antigen: interest for the detection of local recurrence after radical prostatectomy. Prostate 1998;34: 23-28.
5. Luderer AA, Chen YT, Soriano TF, Kramp WJ, Carlson G, Cuny C, Sharp T, Smith W, Petteway J, Brawer MK. Measurement of the proportion of free to total prostate-specific antigen improves diagnostic performance of prostate-specific antigen in the diagnostic gray zone of total prostate-specific antigen. Urology 1995; 46:187-194.
6. Benson MC, Whang IS, Olsson CA, McMahon DJ, Cooner WH. The use of prostate-specific antigen density to enhance the predictive value of intermediate levels of serum prostate specific antigen. J Urol 1992;147:817-821.
7. Carter HB, Pearson JD. Prostate-specific antigen velocity and repeated measures of prostate- specific antigen. Urol Clin North Am 1997;24:333-338.
8. Diamandis EP, Yu H. Prostate-specific antigen and lack of specificity for prostate cells [letter]. Lancet 1995;345:1186.
9. Diamandis EP, Yu H. New biological functions of prostate-specific antigen? J Clin Endocrinol Metab 1995;80:1515-1517.
10. Diamandis EP. Prostate-specific antigen: its usefulness in clinical medicine. Trends Endocr Metab 1998;9:310-316.
11. Elgamal AA, Van de Voorde W, Van Poppel H, Lauweryns J, Baert L. Immunohistochemical localization of prostate-specific markers within the accessory male sex glands of Cowper, Littre, and Morgagni. Urology 1994;44:84-90.
12. Oesterling JE, Tekchandani AH, Martin SK, Bergstralh EJ, Reichstein E, Diamandis EP, Yemoto C, Stamey TA. The periurethral glands do not significantly influence the serum prostate-specific antigen concentration. J Urol 1996;155:1658-1660.
13. Elgamal AA, Ectors NL, Sunardhi-Widyaputra S, Van Poppel HP, Van Damme BJ, Baert LV . Detection of prostate specific antigen in pancreas and salivary glands: a potential impact on prostate cancer overestimation. J Urol 1996;156:464-466.
14. Lopez-Otin C, Diamandis EP. Breast and prostate cancer: an analysis of common epidemiological, genetic, and biochemical features. Endocr Rev 1998;19:365-396.
15. Borchert GH, Melegos DN, Tomlinson G, Giai M, Roagna R, Ponzone R, Sgro L, Diamandis EP. Molecular forms of prostate-specific antigen in the serum of women with benign and malignant breast diseases. Br J Cancer 1997;76:1087-1094.
16. Yu H, Levesque MA, Clark GM, Diamandis EP. Prognostic value of prostate-specific antigen for women with breast cancer: a large United States cohort study. Clin Cancer Res 1998;4:1489-1497.
17. Levesque M, Hu H, D'Costa M, Diamandis EP. Prostate-specific antigen expression by various tumors. J Clin Lab Anal 1995;9: 123-128.
18. Agha AH, Schechter E, Roy JB, Culkin DJ. Prostate-specific antigen is metabolized in the liver. J Urol 1996;155:1332-1335.
19. Bosch X, Bernardich O. Increased serum prostate-specific antigen in a man and a woman with hepatitis A. N Engl J Med 1997;337:1849-1850.
20. National Committee for Clinical Laboratory Standards. Primary reference preparations for standardization and calibration of immunochemical assays for serum prostate antigen (PSA): approved guideline. NCCLS document I/LA 19-A. Wayne, PA: NCCLS; 1997.
21. Standaert B, Denis L. The European randomized study of screening for prostate cancer. Cancer 1997;80:1830-1834.
22. Kabalin JN, Hornberger JC. Prostate-specific antigen is not excreted by human kidney or eliminated by routine hemodialysis. Urology 1991;37:308-310.
23. Monath JR, Burkart JM, Freedman BI, Pittaway DE, Russell GB, Assimos DG. Effects of hemodialysis on prostate-specific antigen. Urology 1993;42:398-400.
24. Williams PB, Eastham JA, Culkin DJ, Mata JA, Venable DD, Sartor O. Influence of hepatic function on serum levels of prostate-specific antigen. J Urol 1997;158:1867-1869.
25. Cetinkaya M, Cetinkaya H, Ulusoy E, Baz S, Memis A, Yasa H, Yanik B, Ozturk B, Uzunalimoghi O. Effect of postnecrotic and alcoholic hepatic cirrhosis on development of benign prostatic hyperplasia. Prostate 1998;36:80-84.
26. Oesterling JE, Jacobsen SJ, Chute CG, Guess HA, Girman CJ, Pauser LA, Lieber MM. Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges. JAMA 1993;270:860-864.
27. Boscato LM, Stuart MC. Heterophilic antibodies: a problem for all immunoassays. Clin Chem 1988;34:27-33.
28. Despres N, Grant AM. Antibody interference in thyroid assays: a potential for clinical misinformation. Clin Chem 1998;44:440-454.
29. Norden AG, Jackson RA, Norden LE, Griffin AJ, Barnes MA, Little JA. Misleading results from immunoassays of serum free thyroxine in the presence of rheumatoid factor. Clin Chem 1997; 43:957-962.
30. Price T, Beatty BG, Beatty JD, McNally AJ. Human anti-murine antibody interference in measurement of carcinoembryonic antigen assessed with a double-antibody enzyme immunoassay. Clin Chem 1991;37:51-57.
31. Reinsberg J. Interference by human antibodies with tumor marker assays. Hybridoma 1995;14:205-208.
32. Stowell LI, Sharman LE, Hamel K. An enzyme-linked immunosorbent assay (ELISA) for prostate-specific antigen. Forensic Sci Int 1991;50:125-138.
33. Williams RC. Rheumatoid factors in subacute bacterial endocarditis and other infectious diseases. Scand J Rheumatol [Suppl] 1988;75:300-308.
34. Roggendorf M, Deinhardt F, Bohm B, Tabor E. Demonstration of a transient rheumatoid factor in the acute phase of hepatitis non A, non B. J Med Virol 1985;15:271-281.
35. Weber TH, Kapyaho KI, Tanner P. Endogenous interference in immunoassays in clinical chemistry. A review. Scand J Clin Lab Invest [Suppl] 1990;201:77-82.
36. Pawarode A, Voravud N, Sriuranpong V, Kullavanijaya P, Patt YZ. Natural history of untreated primary hepatocellular carcinoma: a retrospective study of 157 patients. Am J Clin Oncol 1998;21:386-391.
37. Larcos G, Sorokopud H, Berry G, Farrell GC. Sonographic screening for hepatocellular carcinoma in patients with chronic hepatitis or cirrhosis: an evaluation. AJR 1998;171:433-435.